1. Scrip

Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

 
• By Mandy Jackson

Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.

Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis of Myelofibrosis - Image
Inrebic is only the second drug, after Jakafi, approved for myelofibrosis in the US. • Source: Shutterstock

Ownership of Inrebic (fedratinib) traded hands a few times before it landed at Celgene Corp. for $1.1bn up front in January 2018, so with US Food and Drug Administration approval of the selective JAK2 inhibitor on 16 August it's not just myelofibrosis patients – who haven't had a new drug for their disease in eight years – that will benefit.

Inrebic was approved via priority review two and a half weeks before its 3 September action date to treat US adults with intermediate-2 or high-risk primary or secondary

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.